Melatonin Supplement Testing: Low-Dose Uniformity, Related Substances, and Why Gummies Keep Failing Potency

Melatonin is the best-selling sleep supplement ingredient in North America, with retail sales exceeding $1.3 billion annually. Label doses now span a 30-fold range — from 0.3 mg in micro-dose sublingual tablets to 10 mg in adult gummies. That range creates an analytical and manufacturing problem most brands underestimate: the smaller the target dose, the more catastrophically normal blending variance translates into unit-to-unit potency failures.

At Qalitex, melatonin ranks in our top five ingredients by volume of content uniformity failures. The pattern is consistent across clients: composite assays look acceptable, individual unit testing reveals that 20–40% of low-dose gummies or orally disintegrating tablets (ODTs) fall outside label claim. This article covers the analytical methods, uniformity data, contamination risks, and regulatory nuances that brands need to address before release.

Why low-dose uniformity fails: the math of micro-doses

A 1 mg melatonin gummy weighs approximately 3,500–4,500 mg. The active ingredient represents 0.022–0.029% of the dosage form mass. At 0.3 mg, that fraction drops to 0.007–0.009%. For context, a 500 mg berberine capsule delivers roughly 50–65% active by weight — three orders of magnitude more favorable for blend uniformity.

For raw material and ingredient-level verification, Ayah Labs specializes in contract testing and supplier qualification.

For EU market entry and European regulatory compliance, Care Europe provides expert consulting from Paris.

USP <905> Uniformity of Dosage Units provides the acceptance criteria. Under Stage 1 (n = 10), the acceptance value (AV) must not exceed 15.0, calculated from the mean, the reference value, and individual deviations. For products claiming ≤ 25 mg per unit, the pharmacopeial expectation is content uniformity testing rather than weight variation — meaning each unit is individually assayed.

At Qalitex, we tested content uniformity on five commercial melatonin products across dose levels. The following data represents Stage 1 results (n = 10) on finished units pulled at random from production lots:

Product format	Label claim	Mean assay (% LC)	Range (% LC)	RSD (%)	Units outside 85–115% LC
Compressed tablet	5 mg	97.4%	91–104%	4.1	0 of 10
Compressed tablet	1 mg	93.8%	78–112%	11.6	2 of 10
Pectin gummy	3 mg	101.2%	72–131%	18.9	4 of 10
Pectin gummy	1 mg	88.6%	54–119%	24.7	6 of 10
ODT (sublingual)	0.3 mg	82.3%	41–138%	32.4	7 of 10

The 5 mg compressed tablet passed comfortably. Every other format and dose level in this dataset would fail USP <905> Stage 1. The 0.3 mg ODT showed a 32.4% RSD — meaning individual tablets delivered anywhere from 0.12 mg to 0.41 mg against a 0.3 mg claim.

These numbers are not outliers. They reflect the physical reality of dispersing sub-milligram quantities of a fine powder into a large-mass dosage form. Gummy slurry depositing and ODT direct compression both amplify the problem relative to wet-granulated tablets.

HPLC methods: one molecule, three different extraction challenges

Reversed-phase HPLC with UV detection at 223 nm is the standard quantitation approach for melatonin (N-acetyl-5-methoxytryptamine, MW 232.28). The compound has strong UV absorbance, and reference standards are available from USP (Melatonin RS) and Sigma-Aldrich. A typical validated method uses a C18 column (150 × 4.6 mm, 5 µm), mobile phase of methanol–water (60:40 v/v), flow rate 1.0 mL/min, and injection volume of 20 µL.

The chromatography is straightforward. The sample preparation is where dosage form determines success or failure.

Compressed tablets

Methanol extraction with 15 minutes of sonication, followed by filtration through 0.45 µm PVDF, delivers consistent recoveries of 97–102% for melatonin from standard compressed tablets. Excipients like microcrystalline cellulose, croscarmellose sodium, and magnesium stearate do not interfere.

Gummies

Gummy matrices require enzymatic pre-treatment. At Qalitex, we use pepsin in 0.1 N HCl at 37°C for 90 minutes to digest the gelatin or pectin matrix before methanol extraction. Without enzymatic digestion, recoveries from pectin gummies drop to 65–80% — the gel matrix traps melatonin and resists solvent penetration. Validated recovery with our enzyme-assisted protocol is 94–99%.

Sugar interference is the second gummy-specific challenge. Glucose and corn syrup solids co-extract in methanol and can produce broad baseline disturbances near the melatonin retention window. We add a solid-phase extraction (SPE) cleanup step using C18 cartridges for gummy samples to achieve clean baselines and reliable integration.

Orally disintegrating tablets (ODTs)

ODTs present a unique problem: rapid-dissolve excipients like mannitol, crospovidone, and flavoring agents create a high-excipient, low-active matrix where melatonin may be as little as 0.01% of tablet weight. Direct dissolution in methanol–water followed by centrifugation works for most ODT formulations, with recoveries of 96–101%. The critical validation parameter is confirming that flavoring compounds (menthol, citric acid, natural fruit flavors) do not co-elute with melatonin or its known degradants.

If your testing lab applies a single extraction SOP across tablets, gummies, and ODTs, expect biased results — particularly low recovery from gummies and potential interference in ODTs.

Related substances and synthesis impurities

Melatonin is produced commercially by chemical synthesis (acetylation of 5-methoxytryptamine) or, less commonly, by fermentation. Each route generates a distinct impurity profile. The key related substances that a finished-product spec should address:

Related substance	Origin	Typical limit	Analytical concern
5-Methoxytryptamine	Incomplete acetylation	≤ 0.10%	Co-elutes with melatonin on short C8 columns
N-Acetylserotonin	Side reaction / tryptamine pathway	≤ 0.15%	Structural isomer; requires gradient separation
5-Methoxyindole-3-acetic acid	Oxidative degradation	≤ 0.20%	Increases on stability; degradation indicator
Melatonin-related compound A (USP)	Synthesis byproduct	≤ 0.10%	Specified in USP monograph
Total unspecified impurities	Various	≤ 0.50%	Sum of all peaks above reporting threshold

At Qalitex, we run related substances testing using a gradient HPLC method distinct from the assay method — longer run time (35 minutes vs. 12 minutes for assay), lower wavelength (210 nm for broader impurity detection), and shallower gradient to resolve structurally similar indole compounds. The assay method is optimized for speed and melatonin quantitation; it will not resolve all impurities from each other or from the main peak.

Brands receiving a CoA that reports only “melatonin assay” with no related substances line items should question whether degradants or synthesis impurities are hiding inside an unresolved main peak.

Serotonin contamination: the risk most brands overlook

Serotonin (5-hydroxytryptamine, 5-HT) is biosynthetically adjacent to melatonin — melatonin is synthesized from serotonin in the pineal gland via N-acetylation followed by O-methylation. Some fermentation-derived melatonin raw materials and certain botanical sources (e.g., Hypericum perforatum extracts used in combination sleep products) carry measurable serotonin.

This is not a theoretical concern. A 2023 study published in the Journal of Clinical Sleep Medicine analyzed 30 commercial melatonin supplements and detected serotonin in 26% of products tested, with concentrations ranging from 1 to 75 µg per tablet. Serotonin is pharmacologically active at low oral doses and raises safety questions — particularly for consumers taking SSRIs, MAOIs, or triptans, where exogenous serotonin could contribute to serotonergic syndrome risk.

At Qalitex, we offer serotonin screening as an add-on to melatonin potency testing. The method uses the same HPLC-UV platform with a modified gradient and detection at 275 nm (serotonin’s absorption maximum). Our reporting limit is 0.5 µg per dosage unit. We recommend serotonin screening for:

• Any melatonin raw material sourced from fermentation
• Finished products combining melatonin with botanical sleep ingredients
• Products marketed to children, where conservative contamination limits are appropriate

Stability: melatonin degrades faster than most brands budget for

Melatonin is susceptible to oxidation and photodegradation. The primary degradation product is 5-methoxyindole-3-acetic acid, formed via oxidative deacetylation. In solution or high-moisture matrices (gummies, liquid drops), degradation accelerates significantly.

Stability data from Qalitex-supported programs across formats:

Format	Packaging	12-month retention (25°C/60% RH)	24-month retention	Recommended overage
Compressed tablet	HDPE, desiccant, induction seal	96–99%	92–97%	8%
Compressed tablet	Blister (PVC/Al)	97–100%	94–98%	5%
Pectin gummy	Opaque HDPE, desiccant	88–93%	78–86%	20%
Pectin gummy	Clear PET, no desiccant	76–84%	62–74%	35%+
ODT	Foil pouch, individual wrap	94–98%	89–95%	10%
Liquid drops	Amber glass, dropper	82–90%	68–80%	30%

Gummies in clear packaging lose 25–38% of melatonin potency within 24 months. Liquid drops in poorly sealed containers fare similarly. Brands that apply the 5–8% overage appropriate for compressed tablets to gummy formulations will see potency failures before the printed expiry date — guaranteed.

International regulatory differences: melatonin is not universally a supplement

Brands exporting melatonin products face a fragmented regulatory landscape. Dose limits and product classification vary substantially:

Market	Classification	Maximum permitted dose	Key requirement
United States	Dietary supplement (DSHEA)	No federal cap (market norm 0.3–10 mg)	cGMP per 21 CFR 111; no pre-market approval
Canada	Natural health product (NHP)	Up to 10 mg (NPN required)	Product licence with evidence review
European Union	Varies by member state	1–2 mg in most countries (food supplement); higher doses = medicinal	Novel Food status in some jurisdictions
United Kingdom	Food supplement or medicinal	≤ 1 mg without medicinal classification	MHRA classification above 1 mg
Australia	Schedule 4 prescription medicine	All doses require prescription	Not available OTC
Japan	Not approved as food ingredient	Prohibited in supplements	Import restrictions apply

A product tested and released for the US market at 5 mg per gummy cannot ship to the EU, UK, or Australia without reformulation and reclassification. Testing documentation must match the target jurisdiction’s requirements — potency specification, impurity limits, and sometimes method validation protocols differ between DSHEA compliance and EU food supplement regulations.

At Qalitex, we structure CoAs to support multi-market distribution when brands request it, specifying both USP and Ph. Eur. reference standards where applicable and reporting impurity results against the stricter of the two pharmacopeial limits.

Practical checklist for melatonin brands

1. Run content uniformity on individual units, not composites. USP <905> Stage 1 on 10 units minimum for every production lot, especially for products ≤ 3 mg.

2. Validate HPLC extraction for your specific dosage form. Gummies need enzymatic digestion; ODTs need interference checks against flavoring excipients. Do not accept a generic tablet protocol applied to all formats.

3. Specify related substances limits on your raw material and finished product specs. Include 5-methoxytryptamine, N-acetylserotonin, and total impurities. Require a gradient impurity method, not just an assay.

4. Screen for serotonin contamination. Especially on fermentation-sourced raw material, botanical combination products, and any SKU marketed to children.

5. Generate format-specific stability data. Three lots, real packaging, ICH conditions. Set overages from your own degradation curves — 8% for tablets, 20–35% for gummies, 30%+ for liquids.

6. Confirm regulatory classification for every export market. A 5 mg US product may be an unlicensed medicine in the EU. Align your CoA format and impurity reporting to each jurisdiction before shipment.

7. Test incoming raw material lots individually. Supplier CoAs are starting points, not release data. Run identity confirmation and impurity profiling on every new lot before it enters production.

Melatonin’s simplicity on the label — a single compound, a small dose, a familiar name — disguises the analytical and manufacturing complexity underneath. The brands that invest in dosage-form-specific method validation, individual unit uniformity testing, and real stability programs will hold their label claims through expiry. The ones running composite assays on a generic method will keep producing CoAs that say “pass” while individual gummies deliver half or double the intended dose.

Explore nutraceutical testing and HPLC services for melatonin method development, or visit analytical chemistry for custom impurity profiling. For broader testing program design, read the complete brand guide to lab testing for supplements.

Editorial scope

This article summarizes common lab-testing considerations for brands and is not a substitute for product-specific regulatory or legal advice. Method availability and accreditation scope vary by project — confirm with Qalitex before relying on a test menu for release or registration.